与系统性硬化症相关的肺动脉高血压患者的更好的预后:最近的发展和前景
Maria Boutel1, Athanasia Dara1, Alexandra Arvanitaki2,3
1Fourth Department of Internal Medicine, Hippokration University Hospital, School of Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
Journal of clinical medicine
|October 16, 2024
概括
系统性硬化症相关的肺高血压 (SSc-PH) 需要通过年度查进行早期检测. 及时的组合疗法可以改善存活率,但对于肺部疾病的PH和免疫抑制的作用,需要进行研究.
科学领域:
- 心脏病学 心脏病学
- 类风湿病学 类风湿病学
- 肺部病理学 肺部病理学
背景情况:
- 前毛囊性肺高血压 (PH) 是系统性硬化症 (SSc) 的严重并发症,严重影响患者的发病率,死亡率,预后和生活质量.
- 尽管在管理SSc-肺动脉高血压 (SSc-PAH) 中取得了进展,但患有广泛肺部疾病的前毛细血管SSc-PH的存活率保持不变.
- 目前的指导方针主张每年对SSc患者进行PH查,以早期检测.
研究的目的:
- 突出在SSc患者中早期检测毛囊前PH的关键需求.
- 强调适时和积极的SSc-PAH组合治疗的好处.
- 探索未来的研究方向,包括针对肺部疾病的PH的PAH向治疗和免疫抑制的作用.
主要方法:
- 审查国际专家的共识和在SSc.PH管理的PH管理的指导方针.
- 查算法对诊断延迟和不必要程序的影响分析.
- 在SSc-PAH中评估前期组合向治疗的疗效.
主要成果:
- 每年查算法可以识别高风险的SSc患者,可能减少诊断延迟和不必要的右心导管.
- 在SSc-PAH中早期启动前期组合向治疗与增加的生存率和改善的功能参数有关.
- 目前的治疗方法并未观察到患有广泛肺部疾病的前毛囊性SSc-PH的生存率有显著改善.
结论:
- 早期检测和及时,积极的组合治疗对于改善SSc-PAH的结果至关重要.
- 进一步的研究是必不可少的,以确定PAH向治疗和SSc患者的免疫抑制的有效性PH,特别是那些潜在的肺部疾病.
相关概念视频
01:30Pulmonary Hypertension: Classification and Pathogenesis
152
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
152
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
155
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
155
01:20COPD: Pathogenesis and Clinical Features
239
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
239
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
137
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
137
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
180
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
180